Truist Securities Reiterates Buy on Bristol-Myers Squibb

Benzinga Newsdesk www.benzinga.com Neutral 88.9%

Neg 0% Neu 88.9% Pos 0%

Truist Securities analyst Robyn Karnauskas reiterates Bristol-Myers Squibb (NYSE:BMY) with a Buy.

Comments

No comments yet. Be the first!